- Home
- VRAX vs APM Comparison
VRAX vs APM Comparison
Compare VRAX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- APM
- Stock Information
- Founded
- VRAX 2013
- APM 2010
- Country
- VRAX United Kingdom
- APM United Kingdom
- Employees
- VRAX N/A
- APM N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- APM Health Care
- Exchange
- VRAX Nasdaq
- APM Nasdaq
- Market Cap
- VRAX 5.9M
- APM 6.7M
- IPO Year
- VRAX 2022
- APM 2018
- Fundamental
- Price
- VRAX $1.09
- APM $0.86
- Analyst Decision
- VRAX Strong Buy
- APM
- Analyst Count
- VRAX 1
- APM 0
- Target Price
- VRAX $3.00
- APM N/A
- AVG Volume (30 Days)
- VRAX 129.3K
- APM 30.1K
- Earning Date
- VRAX 02-05-2025
- APM 04-29-2025
- Dividend Yield
- VRAX N/A
- APM N/A
- EPS Growth
- VRAX N/A
- APM N/A
- EPS
- VRAX N/A
- APM 0.00
- Revenue
- VRAX $84,872.00
- APM N/A
- Revenue This Year
- VRAX $5,169.18
- APM $157,729.10
- Revenue Next Year
- VRAX $66.97
- APM N/A
- P/E Ratio
- VRAX N/A
- APM $249.77
- Revenue Growth
- VRAX 7.03
- APM N/A
- 52 Week Low
- VRAX $0.60
- APM $0.46
- 52 Week High
- VRAX $9.00
- APM $11.19
- Technical
- Relative Strength Index (RSI)
- VRAX 32.51
- APM 36.58
- Support Level
- VRAX $1.10
- APM $0.85
- Resistance Level
- VRAX $1.35
- APM $1.00
- Average True Range (ATR)
- VRAX 0.11
- APM 0.07
- MACD
- VRAX 0.00
- APM 0.00
- Stochastic Oscillator
- VRAX 6.77
- APM 0.93
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.